RxDoctor Payments Data

Tracy Persily, DO

Family Medicine · Willingboro, NJNPI 1568804912

Payments from drug & device makers

$2,184in general payments, 2019–2025

Across 64 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$858
  • Novo Nordisk$789
  • Amgen$358
  • Lilly USA, LLC$108
  • Astellas Pharma US Inc$17
  • Merck$14
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$2,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,184 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,804
Medicare patients
206
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$93,776
JardianceEmpagliflozin46$66,054
MounjaroTirzepatide17$28,647
EliquisApixaban14$20,448
Breo ElliptaFluticasone/Vilanterol42$19,039
FarxigaDapagliflozin Propanediol21$15,631
WegovySemaglutide11$14,357
XareltoRivaroxaban18$13,225
Spiriva RespimatTiotropium Bromide20$10,405
MyrbetriqMirabegron13$6,772
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,836
Atorvastatin Calcium474$4,616
Diclofenac Sodium28$3,725
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,479
SymbicortBudesonide/Formoterol Fumarate12$2,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$789$108,13373 claims
Lilly USA, LLCMounjaro$108$28,64717 claims
GSKBreo Ellipta, Anoro Ellipta$14$23,87554 claims
AstraZenecaFarxiga, Symbicort$13$18,39233 claims
Astellas Pharma US IncMyrbetriq$17$6,77213 claims
AbbVieSynthroid$858$1,36127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Willingboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →